Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 19/20 | 0.78 |
| ▸ | ITGB3 | P05106 | 18/20 | 0.78 |
| ▸ | ITGA2B | P08514 | 15/20 | 0.75 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.48 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7347222 | 0.95 | ITGB3 (0.71) | ITGAVITGB3ITGA2B | |
| SCHEMBL7356151 | 0.95 | ITGB3 (0.70) | ITGAVITGB3ITGA2B | |
| SCHEMBL7349313 | 0.89 | ITGAV (0.62) | ITGAVITGB3ITGA2B | |
| SCHEMBL7353336 | 0.89 | ITGB3 (0.72) | ITGAVITGB3ITGA2B | |
| SCHEMBL7985900 | 0.88 | ITGB3 (0.61) | ITGAVITGB3ITGA2B | |
| SCHEMBL7985902 | 0.88 | ITGB3 (1.00) | ITGAVITGB3ITGA2B | |
| SCHEMBL7352205 | 0.87 | ITGB3 (0.67) | ITGAVITGB3ITGA2B | |
| SCHEMBL4204480 | 0.86 | ITGB3 (1.00) | ITGAVITGB3ITGA2B | |
| SCHEMBL7985820 | 0.86 | ITGB3 (1.00) | ITGAVITGB3ITGA2B | |
| SCHEMBL7979373 | 0.85 | ITGAV (0.75) | ITGAVITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6214834-B1 | ANGIOGENESIS INHIBITORS; ANTIINFLAMMATORY AGENTS; ANTICANCER AGENTS | DUPONT PHARMACEUTICALS COMPANY | 2001-04-10 | — | — | US | claimed |
| EP-0939757-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | Dupont Pharmaceuticals Company (US) | 1999-09-08 | — | — | EP | claimed |
| WO-1997023480-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-07-03 | — | — | WO | claimed |
| US-6214834-B1 | ANGIOGENESIS INHIBITORS; ANTIINFLAMMATORY AGENTS; ANTICANCER AGENTS | DUPONT PHARMACEUTICALS COMPANY | 2001-04-10 | — | — | US | disclosed |